Drugs / Autologous EPCs Transfected with human eNOS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00936819 | Jul 2013 → Mar 2020 overdue | myocardial infarction | Ottawa Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT03001414 | Sep 2017 → May 2023 | pulmonary hypertension | Northern Therapeutics | Terminated | Missed primary Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous EPCs transfected with human eNOS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03001414 ↗ |
| Action | Restore | “SAPPHIRE will use autologous progenitor cell-based gene delivery to enhance lung microvascular repair and regeneration in patients with severe symptomatic PAH.” NCT03001414 ↗ |
| Route | Other | “Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery” NCT00936819 ↗ |